Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral reparixin for cancer-related fatigue in breast cancer patients receiving taxane chemotherapy
2021-000382-32Phase 2Terminated
- Sponsor
- Dompé
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer-related fatigue (CRF) and breast cancer comparing Reparixin with Placebo (2 arms). Primary endpoint: Primary Efficacy Assessment. Started May 2021; status: terminated.
02
Drugs
reparixin
03
Conditions
cancer-related fatigue (CRF)breast cancer
Beyond the preview
Go deeper on 2021-000382-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000382-32.